PROM1 and hepatocellular carcinoma: In recent phase I clinical trial for CART-CD133 therapy [116], 23 patients were enrolled, including 14 hepatocellular carcinomas (HCC), 7 pancreatic carcinomas, and 2 colorectal carcinomas.